Literature DB >> 24218002

In reply.

James Yao1, Diane Reidy Lagunes, Matthew H Kulke.   

Abstract

Mesh：

Year:  2013        PMID： 24218002      PMCID： PMC3825312          DOI： 10.1634/theoncologist.2013-0242

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  10 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

Review 2.  Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.

Authors:  K Oberg; S Jelic
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

3.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  K Öberg; U Knigge; D Kwekkeboom; A Perren
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.

Authors:  Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

5.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Authors:  C G Moertel; L K Kvols; M J O'Connell; J Rubin
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

Review 6.  The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.

Authors:  David S Klimstra; Irvin R Modlin; Domenico Coppola; Ricardo V Lloyd; Saul Suster
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

7.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

8.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Authors:  Cristina R Ferrone; Laura H Tang; James Tomlinson; Mithat Gonen; Steven N Hochwald; Murray F Brennan; David S Klimstra; Peter J Allen
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

Review 9.  Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.

Authors:  David S Klimstra
Journal:  Semin Oncol       Date:  2013-02       Impact factor: 4.929

Review 10.  Prognostic factors in gastrointestinal endocrine tumors.

Authors:  Guido Rindi; Tiziana D'Adda; Elisabetta Froio; Giovanni Fellegara; Cesare Bordi
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.